카지노 바카라 and Irinotecan combination therapy data poster released
[by Ji, Yong Jun] Idience, a new drug development subsidiary of the Ildong Pharmaceutical Group, announced on May 29 that it will present clinical research findings on the combination therapy of its PARP inhibitor anticancer drug candidate, 'venadaparib,' at the upcoming 2025 American Society of Clinical Oncology (ASCO) annual meeting.
The 카지노 바카라 Annual Meeting is the world’s largest oncology conference, bringing together oncologists, researchers, healthcare professionals, and industry leaders from around the globe. This year’s event will take place in Chicago, USA, from May 30 to June 3 (local time).
카지노 바카라 plans to present the research findings from an exploratory analysis of its multinational Phase 1b/2a clinical trial (NCT04725994) investigating the combination therapy of 'venadaparib and Irinotecan' in patients with metastatic gastric cancer (mGC) who have undergone third-line or later treatments. The results will be shared in the form of a 'poster' presentation.
카지노 바카라 is developing a novel anticancer treatment for third-line or later-stage metastatic gastric cancer by combining venadaparib, a PARP inhibitor with a new mechanism of action, and Irinotecan, a conventional chemotherapy anticancer drug. The company emphasized the significant unmet medical need in this patient population, noting that the median progression-free survival (mPFS) with current standard treatments remains at only two months.
According to 카지노 바카라, a significant correlation was observed between the efficacy of the combination therapy using venadaparib in metastatic gastric cancer patients and the presence of homologous recombination deficiency (HRD) gene mutations. In particular, the therapeutic potential was more pronounced in patients harboring HRD gene mutations.
In the Phase 1b/2a 카지노 바카라 trial evaluating the combination therapy of Venadaparib and Irinotecan, the median progression-free survival (mPFS) was reported as 4.2 months (95% CI: 2.9–5.5), while the median overall survival (mOS) reached 8.0 months (95% CI: 6.7–11.4). Notably, in the subgroup of patients with homologous recombination deficiency (HRD), including mutations in genes such as ATM or BRCA1/2—the mPFS extended to 8.3 months (95% CI: 1.2–23.6), and the mOS was 9.9 months (95% CI: 6.7–33.9). Adverse events were observed at comparable levels irrespective of HRD mutation status.
“We believe that being selected as a presentation topic at the world’s most prestigious academic forum in clinical oncology serves as a valuable opportunity to further showcase the competitiveness of venadaparib and its potential in the development of novel anticancer treatments,” said Lee Won-sik, CEO of 카지노 바카라.